OncoMatch/Clinical Trials/NCT03351842

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Is NCT03351842 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies cis Platinum/Carboplatin, Pemetrexed Disodium for chemotherapy, adjuvant.

Phase 2RecruitingShanghai Pulmonary Hospital, Shanghai, ChinaNCT03351842Data as of May 2026

Treatment: cis Platinum/Carboplatin, Pemetrexed Disodium — Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage I

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiation therapy

Lab requirements

Blood counts

granulocytes >= 1,800/ul; platelets >= 100,000/ul

Liver function

bilirubin < 1.5 mg/dl; sgot (ast) < 2.0 x uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify